A Smartphone App Can Help Men Last Longer in Bed

Why It Matters

The app demonstrates that digital behavioural therapy can effectively address a common sexual dysfunction, offering a private, drug‑free alternative that could reshape urological care and expand the digital health market.

Key Takeaways

• App increased latency from 61s to 125s in 4 weeks.
• 22% of users no longer met PE criteria after trial.
• Study involved 80 men, 66 completed 12‑week protocol.
• Combines pelvic floor, mindfulness, CBT, and arousal awareness.
• Digital therapy offers discreet, drug‑free alternative to pills.

Pulse Analysis

Premature ejaculation affects roughly one in three men, making it the most prevalent male sexual dysfunction worldwide. Traditional interventions—topical anesthetics, selective serotonin reuptake inhibitors, or other prescription drugs—often require pre‑medication, carry side‑effects, and can feel impersonal. As patients increasingly seek privacy and autonomy, clinicians are turning to behavioral solutions that can be delivered at scale. The rise of mobile health platforms provides a conduit for evidence‑based techniques, yet few have been rigorously tested in controlled settings.

The Melonga app, developed by Dutch start‑up Prognoix, integrates arousal‑awareness training, pelvic‑floor exercises, mindfulness, and cognitive‑behavioural strategies into a structured curriculum. In the trial, 80 men were randomized, and 66 completed the 12‑week protocol. Participants using the app more than doubled their intravaginal ejaculation latency time—from 61 seconds at baseline to 125 seconds—within a month, while the control group showed negligible change. Notably, 22% of users fell below the clinical threshold for premature ejaculation after the program, indicating a meaningful shift in both physiological response and psychological confidence.

These findings underscore the commercial and clinical potential of digital therapeutics in urology. A discreet, app‑based solution reduces stigma, eliminates the need for in‑person consultations, and aligns with the broader trend toward personalized, data‑driven health care. As insurers and employers explore coverage for proven digital interventions, startups like Prognoix could capture a sizable share of a market traditionally dominated by pharmaceuticals. Future research should expand sample sizes, assess long‑term durability, and compare app‑based outcomes directly against standard drug regimens to solidify its role in treatment guidelines.